Advisory Services Network’s Titan Pharmaceuticals TTNP Stock Holding History

Advisory Services Network’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-450	Closed	-$23K	–	3087
2021 Q2	$23K	Buy	+450	New	+$22.5K	﹤0.01%	2445
2021 Q1	–	Sell	-100	Closed	-$7K	–	2822
2020 Q4	$7K	Buy	+100	New	+$7.9K	﹤0.01%	2609
2016 Q3	–	Hold	0	–	–	–	2069
2016 Q2	–	Hold	0	–	–	–	1946

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Trust Company Manhattan, Kansas $1.11B AUM 13.1% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Advisory Services Network's TTNP Position: Q3 2021 in Review

Advisory Services Network sold out of Titan Pharmaceuticals (TTNP) in Q3 2021, closing a stake of 450 shares — an estimated $23K sold.

Advisory Services Network first reported a position in TTNP in Q4 2020 and held it in 2 quarters. The position peaked at $23K in Q2 2021. 12 funds tracked by Wall St. Rank hold TTNP as of Q3 2021.

Advisory Services Network reported no remaining Titan Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Advisory Services Network sold 450 Titan Pharmaceuticals shares in Q3 2021, an estimated $23K.
Advisory Services Network first reported a position in Titan Pharmaceuticals in Q4 2020 and held it in 2 quarters.
Advisory Services Network's Titan Pharmaceuticals position peaked at $23K in Q2 2021.
12 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2021.

Based on Advisory Services Network's 13F filing for Q3 2021, filed 5 Nov 2021.